Evidence map›Paper›PMID 42391786›Full record

ArticleNeoplasia (New York, N.Y.)2026

The importance of HPV testing in oropharyngeal cancer in two US populations.

M M Lawas, M Hsieh, S Patil, E Mohebbi, R Zhang, J Ahn, W Benjamin, S B Chinn, M Witek, B Mabvakure and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neoplasia (New York, N.Y.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

M M LawasUniversity of Michigan Medical School Department of Computational Medicine and Bioinformatics, Ann Arbor, MI, USA.
M HsiehLouisiana State University Health Sciences Center School of Public Health, New Orleans, LA, USA.
S PatilGeorgetown University Medical Center, Department of Oncology, Washington, DC, USA.
E MohebbiGeorgetown University Medical Center, Department of Oncology, Washington, DC, USA.
R ZhangGeorgetown University Medical Center, Department of Oncology, Washington, DC, USA.
J AhnGeorgetown University Medical Center, Department of Oncology, Washington, DC, USA.
W BenjaminUniversity of Michigan Medical School. Current affiliation: Department of Otolaryngology, Head and Neck Surgery, Mass Eye and Ear, Boston, MA, USA.
S B ChinnUniversity of Michigan Medical School. Current affiliation: Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA, USA.
M WitekMedstar Georgetown University Hospital Radiation Medicine, Washington, DC, USA; University of Michigan School of Dentistry, Ann Arbor, MI, USA.
B MabvakureGeorgetown University Medical Center, Department of Oncology, Washington, DC, USA; University of Michigan School of Dentistry, Ann Arbor, MI, USA.
A DuttargiGeorgetown University Medical Center, Department of Oncology, Washington, DC, USA.
L M CruzGeorgetown University Medical Center, Department of Oncology, Washington, DC, USA.
B GarbUniversity of Michigan Medical School Department of Computational Medicine and Bioinformatics, Ann Arbor, MI, USA.
S LiUniversity of Michigan Medical School Department of Computational Medicine and Bioinformatics, Ann Arbor, MI, USA.
N J D'SilvaUniversity of Michigan School of Dentistry, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, USA.
M A SartorUniversity of Michigan Medical School Department of Computational Medicine and Bioinformatics, Ann Arbor, MI, USA; University of Michigan Rogel Cancer Center, USA. Electronic address: sartorma@umich.edu.
L S RozekGeorgetown University Medical Center, Department of Oncology, Washington, DC, USA. Electronic address: lr898@georgetown.edu.

Funding

Therapeutic Potential and Mechanism of Action of Potent Small Molecule InhibitorsP50CA097248 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI NOR, JACQUES EDUARDO · 2002 to 2013
$25.3M
Downstream effects of HPV integration on survival/metastasis in oropharyngeal cancerR01CA250214 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI D'SILVA, NISHA J, ROZEK, LAURA · 2020 to 2024
$3.1M
NCI NIH HHS P50 CA097248NCI NIH HHS R01 CA250214
6 · The paper itself

Abstract

backgroundHPV-positive (HPV+) oropharyngeal squamous cell carcinoma (OPSCC) patients have improved survival compared to HPV-negative OPSCC (HPV-) patients (5-year survival rates of ∼80% versus ∼40%). The predictive value of p16 immunohistochemistry (IHC) for HPV+ OPSCC, the most widely used clinical test for HPV status, varies by HPV+ OPSCC prevalence in geographically different populations, but variation within a region is not well described.

methodsWe analyzed p16 IHC and survival in two geographically and demographically diverse OPSCC cohorts of African American (AA, n = 177, Louisiana Tumor Registry) and non-Hispanic white (NHW, n = 392, University of Michigan) patients.

resultsHPV+ prevalence was 29.3% in AA versus 86.8% in NHW. p16+ OPSCC was associated with significantly better survival in NHW than in AA patients (HR=4.65, 95% CI: 2.88-7.51, Cox p < 0.0001), adjusting for covariates. AA p16- had worse survival than NHW p16- (log-rank p < 0.001). p16 was less predictive of HPV RNA status for AA than NHW patients (positive predictive value = 65.4% vs. 94.9%, p < 0.05). Among HPV RNA+ patients (79 NHW,17 AA), AA had worse survival than NHW (log-rank p < 0.001).

conclusionsSurvival disparities exist after accounting for heterogeneous HPV+ tumor rates. The PPV of p16 for HPV RNA-defined OPSCC is substantially lower in AA vs NHW patients. Guidelines for HPV testing in OPSCC should be attentive to factors beyond geography.

Indexed as

Human Papillomavirus VirusesOropharyngeal NeoplasmsPapillomavirus InfectionsAgedBlack or African AmericanCyclin-Dependent Kinase Inhibitor p16FemaleHumansImmunohistochemistryLouisianaMaleMiddle AgedPrevalencePrognosisUnited StatesWhiteCyclin-Dependent Kinase Inhibitor p16EpidemiologyHead and neck cancerHealth disparitiesHPVOPSCCPrecision oncology

Identifiers

PMID42391786
PMCPMC13352036

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.